Successful "in-flight" activation of natural killer cells during long-distance shipping

Transfusion

Volumn 53, Issue 2, 2013, Pages 398-403

  Koepsell, Scott A ^a   Kadidlo, Diane M ^a   Fautsch, Susan ^a   McCullough, Jeffrey ^a   Klingemann, Hans ^a   Wagner, John E ^a   Miller, Jeffrey S ^a   McKenna, David H ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTOXIN; INTERLEUKIN 2;

APHERESIS; ARTICLE; CD3+ T LYMPHOCYTE; CELL ACTIVATION; CELL COUNT; CELL THERAPY; CELL VIABILITY; CYTOTOXICITY; IMMUNOPHENOTYPING; MONONUCLEAR CELL; NATURAL KILLER CELL; QUALITY CONTROL; SHIPPING; T CELL DEPLETION;

BLOOD PRESERVATION; CLINICAL TRIALS, PHASE I AS TOPIC; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-2; K562 CELLS; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; TEMPERATURE; TIME FACTORS; TRAVEL; TUMOR CELLS, CULTURED;

EID: 84873450267     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2012.03695.x     Document Type: Article

References (9)

1. Moretta L, Locatelli F, Pende D, Marcenaro E, Mingari MC, Moretta A,. Killer Ig-like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation. Blood 2011; 117: 764-71.
2. Symons HJ, Leffell MS, Rossiter ND, Zahurak M, Jones RJ, Fuchs EJ,. Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation. Biol Blood Marrow Transplant 2010; 16: 533-42.
3. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, McKenna D, Le C, Defor TE, Burns LJ, Orchard PJ, Blazar BR, Wagner JE, Slungaard A, Weisdorf DJ, Okazaki IJ, McGlave PB,. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005; 105: 3051-7.
4. McKenna DH Jr, Sumstad D, Bostrom N, Kadidlo DM, Fautsch S, McNearney S, Dewaard R, McGlave PB, Weisdorf DJ, Wagner JE, McCullough J, Miller JS,. Good manufacturing practices production of natural killer cells for immunotherapy: a six-year single-institution experience. Transfusion 2007; 47: 520-8.
5. Marti F, Miralles A, Peiro M, Amill B, de Dalmases C, Pinol G, Rueda F, Garcia J,. Differential effect of cryopreservation on natural killer cell and lymphokine-activated killer cell activities. Transfusion 1993; 33: 651-5.
6. Miller JS, Oelkers S, Verfaillie C, McGlave P,. Role of monocytes in the expansion of human activated natural killer cells. Blood 1992; 80: 2221-9.
7. Sutlu T, Alici E,. Natural killer cell-based immunotherapy in cancer: current insights and future prospects. J Intern Med 2009; 266: 154-81.
8. Whiteside TL, Griffin DL, Stanson J, Gooding W, McKenna D, Sumstad D, Kadidlo D, Gee A, Durett A, Lindblad R, Wood D, Styers D,. Shipping of therapeutic somatic cell products. Cytotherapy 2011; 13: 201-13.
9. Klingemann H, Grodman C, Cuttler E, Duque M, Kadidlo D, Klein A, Sprague KA, Miller KB, Comenzo RL, Kewalramani T, Yu N, Van Etten R, McKenna D,. Autologous stem cell transplant recipients tolerate MHC haplotype-mismatched NK cell enriched donor lymphocyte infusions. Submitted.